P
Partner Therapeutics
A Boston, MA-based oncology company,
About Partner Therapeutics
Partnertx.com is a commercial biopharmaceutical startup that focuses on the development and distribution of therapies for serious diseases, including cancer. Their primary product is LEUKINE® (sargramostim), a drug that has shown potential in improving lung health and is currently being researched for its potential role in the treatment of COVID-19. The company's business model revolves around the continuous development of this drug, based on independent scientific data and their understanding of its mechanism of action.
The company serves a broad range of clients, primarily patients suffering from serious diseases, and operates in the biopharmaceutical market. They generate revenue through the sale of their developed drugs to healthcare providers and patients. Their approach to business is proactive, as they actively engage with leading specialists in pulmonology, immunology, and other fields to initiate research and identify new opportunities for their drug to make a difference for patients.
In the future, Partnertx.com plans to apply this approach to new areas of research, aiming to make a positive difference for patients with many serious diseases. Their mission is to improve the lives of patients, and they are committed to identifying opportunities where their drug can make a significant impact.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lexington, United States
- Employees
- 188
- Open positions
- 1
- Dealroom signal
- 68.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2018 | $60M | $240M | Adams Street Partners · Midcap Financial · Perceptive Advisors | — |
Growth signals
Latest recorded traffic for Partner Therapeutics is 5.6K monthly website visits, down 18.8% over the last three months. Partner Therapeutics's team grew 0.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Adams Street Partners
Midcap Financial
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Partner Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Partner Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.